Catatonia

Rishi Sunak has ripped up decades of cross-party consensus on climate change

Retrieved on: 
Tuesday, September 26, 2023
Environmental Pollution (journal), Speech, Politics, Leadership, Catatonia, Policy, Sun, Ford, Tax, Hope, Fire, Energy, Stern Review, Negotiation, Kyoto Protocol, Carbon, Foundation, Government, Science, Royal Commission on Environmental Pollution, Kyoto, Climate, MP, Climate change, Flood, Royal commission, Patient, Rishi Sunak, Relaxation, Meat, Economics, Consciousness, Renewable energy, Awakenings

The acclaimed 1990 film Awakenings tells the story of a neurologist who discovers a drug which rouses catatonic patients from decades of “sleep”.

Key Points: 
  • The acclaimed 1990 film Awakenings tells the story of a neurologist who discovers a drug which rouses catatonic patients from decades of “sleep”.
  • I had been there when the UK miraculously built a cross-party consensus around climate change.
  • I’d had what you might call a front row seat as a political consensus on climate change emerged in the UK.
  • But during the long and uncomfortable 25 minutes of Sunak’s speech, I felt I was witnessing a homage to catatonia.

Delay is costly

    • Delay is tantamount to capitulation.
    • A key economic principle follows from this: the sooner you act, the lower the final bill.
    • Those costs are already being counted: fires in Europe and Canada, droughts in North America and Africa, floods in Libya.
    • It’s no surprise to find an embattled political party trying to draw clear blue water between itself and the opposition.
    • Not content with betraying the interests of the future, Sunak’s speech has helped turn climate change into a sordid culture war.
    • Every Wednesday, The Conversation’s environment editor writes Imagine, a short email that goes a little deeper into just one climate issue.

ASF Releases Request for Applications for Undergraduate Summer Research Projects

Retrieved on: 
Wednesday, February 8, 2023
Autism Science Foundation, Sleep, Immunology, Student, Epigenomics, Anatomy, Pharmacology, Neuropathology, Diagnosis, Language, Neuroscience, Catatonia, Behavior, Research, Self-harm, Genetics, Policy, Spectrum, Priority, ASF, Genomics, Multimedia, Employment, Learning, Epilepsy, Communication, Vaccine, Tutoring, Nursing

NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The Autism Science Foundation (ASF), a nonprofit organization dedicated to supporting and funding innovative autism research, has released a request for applications for undergraduate summer research fellowships and invites applications from highly qualified undergraduates interested in pursuing basic and clinical research relevant to autism spectrum disorders during the summer.

Key Points: 
  • NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The Autism Science Foundation (ASF), a nonprofit organization dedicated to supporting and funding innovative autism research, has released a request for applications for undergraduate summer research fellowships and invites applications from highly qualified undergraduates interested in pursuing basic and clinical research relevant to autism spectrum disorders during the summer.
  • The proposed research must be scientifically linked to autism.
  • Students must not have received a bachelor's degree at the time the project starts over the summer.
  • Read the full Request for Applications here: https://autismsciencefoundation.org/apply-for-an-undergraduate-summer-re...
    View original content to download multimedia: https://www.prnewswire.com/news-releases/asf-releases-request-for-applic...

Autism Science Foundation Awards First Round of Profound Autism Pilot Grants

Retrieved on: 
Wednesday, January 11, 2023
AAC, Infection, Catatonia, Autism Science Foundation, Pain, Communication, Dementia, Sleep, Hospital, Government budget balance, Intellectual disability, Emotional disturbance, Patient, Mouse, Self-Injurious Behavior Inhibiting System, Research, IPad, ASF, Vaccine, Health insurance, Residential care, Autism

NEW YORK, Jan. 11, 2023 /PRNewswire/ -- The Autism Science Foundation (ASF), a nonprofit organization dedicated to funding innovative autism research and supporting families facing autism, today announced the recipients of its inaugural profound autism pilot grants. Four grants will be awarded to researchers for projects examining sleep, neuropsychiatric regression, and self-injurious behaviors, as well as methods to improve access to communications systems for people with profound autism.

Key Points: 
  • This first-of-its-kind funding mechanism supports research on autistic people with the highest support needs, who are demonstrably underrepresented in research
    NEW YORK, Jan. 11, 2023 /PRNewswire/ -- The Autism Science Foundation (ASF), a nonprofit organization dedicated to funding innovative autism research and supporting families facing autism, today announced the recipients of its inaugural profound autism pilot grants.
  • "These new projects will ensure that those across the spectrum are represented in autism research" said ASF Chief Science Officer Dr. Alycia Halladay.
  • Existing studies of sleep in autism have mostly excluded children with profound autism.
  • This regression has been linked to infection in girls with Phelan McDermid Syndrome, a genetic condition associated with profound autism.

Families of Those Living with a Severe Neurodevelopmental Disorder to Provide Perspective to FDA to Help Expedite New Treatments

Retrieved on: 
Tuesday, October 11, 2022
FDA, Healthcare Reform, Pharmaceutical, Managed Care, Philanthropy, Neurology, Public Policy, Government, Genetics, Foundation, Family, Science, Biotechnology, Consumer, Health, Research, Quality of life, SHANK3, Disease, Efficiency, Degenerative disease, Hypotonia, Regulation of tobacco by the U.S. Food and Drug Administration, Deletion, Patient, Drug development, Biology, Research, Partnership, Gene, ICD-10, Food, Human, PMS, PMSF, Disorder, Epilepsy, Doctor of Philosophy, Catatonia, Marketing, Awareness, Intellectual disability, Autism, Anxiety, Child, Biomarker, Dravet Syndrome Foundation, Failure, Lists of diseases, Sleep, FDA, Pharmaceutical industry, Management

This EL-PFDD meeting is an indispensable part of CureSHANKs mission to overcome critical barriers to the development of successful treatments for PMS, said CureSHANK President Geraldine Bliss.

Key Points: 
  • This EL-PFDD meeting is an indispensable part of CureSHANKs mission to overcome critical barriers to the development of successful treatments for PMS, said CureSHANK President Geraldine Bliss.
  • The more the FDA and other stakeholders understand the patient perspective, the more quickly treatments that make a difference to those in the PMS community will be brought to those living with this profoundly debilitating genetic condition.
  • For additional information on the EL-PFDD including access to the live discussion with the FDA on November 8, please visit: https://www.cureshank.org/elpfdd-meeting .
  • CureSHANK was founded in 2019 by Geraldine Bliss, Abby Lievense and Paulina Rychenkova, each the parent of a child living with PMS.

Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities

Retrieved on: 
Monday, December 20, 2021
Faculty, Therapy, Faculty of Pharmaceutical Medicine, Electroconvulsive therapy, Ketamine, UCLouvain Faculty of Economic, Social and Political Sciences and Communication, Genomics, Psychiatry, HuffPost, LC-MS, SAN, Royal college, Royal London Hospital, Wharton School of the University of Pennsylvania, The Wall Street Journal, University of Cambridge, The Washington Post, Royal Society, NASDAQ, Physician, Pharmaceutical medicine, University, Research, MB BS, Patient, Royal, CB, MB, Transcranial magnetic stimulation, Enzyme, Master, University of Pennsylvania, HPLC, Catatonia, Efficiency, MD, STAT, GLOBE, Fermentation, Cannabinoid, GW Pharmaceuticals, Pharmaceutical industry, Cannabidiol, Medicine, Atlantic Ocean

His other higher degrees include an MD from The University of Cambridge and a Diploma in Pharmaceutical Medicine.

Key Points: 
  • His other higher degrees include an MD from The University of Cambridge and a Diploma in Pharmaceutical Medicine.
  • In addition, he holds a diploma in Pharmaceutical Business Management from The Wharton School at The University of Pennsylvania.
  • CB Therapeutics produces high-value molecules, compounds, and rare ingredients from simple sugars utilizing yeast and the process of fermentation.
  • CB Therapeutics' expertise in synthetic genomics and bio-engineering has significantly advanced its proprietary production platform of microorganisms, enzymes, and production processes.

The Madness of Fear

Retrieved on: 
Monday, October 29, 2018
Psychiatry, Schizophrenia, Abnormal psychology, Psychosis, Psychopathological syndromes, Psychopathology, Catatonia, Max Fink

It is not a form of "schizophrenia," and does not respond well to the anti-schizophrenic drugs that many doctors might be inclined to use.

Key Points: 
  • It is not a form of "schizophrenia," and does not respond well to the anti-schizophrenic drugs that many doctors might be inclined to use.
  • The story of this remarkable medical milestone is highlighted in the new Oxford University Press publication, The Madness of Fear: A History of Catatonia, written by the historian of medicine Edward Shorter and the clinician neuropsychiatrist Max Fink.
  • This important book will help clinicians and the educated public recognize the disorder and ask for its proper treatment.
  • In The Madness of Fear, Drs.